COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer.
作者信息
Zeng Cong, Evans John P, Chakravarthy Karthik, Qu Panke, Reisinger Sarah, Song No-Joon, Rubinstein Mark P, Shields Peter G, Li Zihai, Liu Shan-Lu
机构信息
Center for Retrovirus Research, Ohio State University, Columbus, OH 43210, USA; Department of Veterinary Biosciences, Ohio State University, Columbus, OH 43210, USA.
Center for Retrovirus Research, Ohio State University, Columbus, OH 43210, USA; Department of Veterinary Biosciences, Ohio State University, Columbus, OH 43210, USA; Molecular, Cellular and Developmental Biology Program, Ohio State University, Columbus, OH 43210, USA.
出版信息
Cancer Cell. 2022 Feb 14;40(2):117-119. doi: 10.1016/j.ccell.2021.12.014. Epub 2021 Dec 30.
Abstract
摘要
相似文献
1
COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer.新冠病毒mRNA加强疫苗对癌症患者抵御新冠病毒奥密克戎变种有很强的保护作用。
Cancer Cell. 2022 Feb 14;40(2):117-119. doi: 10.1016/j.ccell.2021.12.014. Epub 2021 Dec 30.
2
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant.mRNA-1273 和 BNT162b2 mRNA 疫苗对 SARS-CoV-2 奥密克戎变异株的中和活性降低。
Cell Rep Med. 2022 Jan 24;3(2):100529. doi: 10.1016/j.xcrm.2022.100529. eCollection 2022 Feb 15.
3
Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.评估新冠疫苗需要标准化的中和抗体检测。
EBioMedicine. 2021 Nov;73:103677. doi: 10.1016/j.ebiom.2021.103677. Epub 2021 Nov 3.
4
Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants.疫苗诱导产生的抗体水平与针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）及其变体的中和活性之间的相关性。
Clin Transl Med. 2021 Dec;11(12):e644. doi: 10.1002/ctm2.644.
5
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial.首次感染 SARS-CoV-2 奥密克戎变异株可增强 mRNA 疫苗接种者的免疫效果：PRIBIVAC 随机临床试验第一阶段的最终结果。
EBioMedicine. 2024 Sep;107:105275. doi: 10.1016/j.ebiom.2024.105275. Epub 2024 Aug 12.
6
Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy.COVID-19 加强疫苗接种的免疫原性和安全性：一项基于人群的临床试验，旨在确定最佳的疫苗接种策略。
J Clin Virol. 2024 Aug;173:105661. doi: 10.1016/j.jcv.2024.105661. Epub 2024 Feb 28.
7
Distinct T cell responsiveness to different COVID-19 vaccines and cross-reactivity to SARS-CoV-2 variants with age and CMV status.不同 COVID-19 疫苗引起的 T 细胞反应不同，以及与年龄和 CMV 状态相关的对 SARS-CoV-2 变体的交叉反应性。
Front Immunol. 2024 May 7;15:1392477. doi: 10.3389/fimmu.2024.1392477. eCollection 2024.
8
Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.恢复期和疫苗血清对 SARS-CoV-2 奥密克戎变体的活性。
Nature. 2022 Feb;602(7898):682-688. doi: 10.1038/s41586-022-04399-5. Epub 2021 Dec 31.
9
Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.BNT162b2 或 mRNA-1273 异源加强接种后 SARS-CoV-2 IgA、IgG、中和和总抗体反应的随访和比较评估。
Influenza Other Respir Viruses. 2024 May;18(5):e13290. doi: 10.1111/irv.13290.
10
Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program.新型冠状病毒肺炎疫苗接种计划启动后，免疫缺陷病（IEI）患者接种新型冠状病毒肺炎加强针的免疫原性及其一年临床随访
Front Immunol. 2024 Apr 18;15:1390022. doi: 10.3389/fimmu.2024.1390022. eCollection 2024.
引用本文的文献
1
COVID-19 related symptoms and the second infection status of SARS-CoV-2 in patients with lung cancer: A single-center, six-month longitudinal observational study.肺癌患者中与COVID-19相关的症状及SARS-CoV-2的二次感染情况：一项单中心、为期六个月的纵向观察性研究。
Asia Pac J Oncol Nurs. 2025 May 29;12:100735. doi: 10.1016/j.apjon.2025.100735. eCollection 2025 Dec.
2
COVID-19 inactivated booster vaccines elicit strong protection against SARS-CoV-2 wild-type and Omicron variant in patients with breast cancer.新冠病毒灭活加强疫苗对乳腺癌患者的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）野生型和奥密克戎变种引发强大保护作用。
Front Med (Lausanne). 2025 Apr 1;12:1516492. doi: 10.3389/fmed.2025.1516492. eCollection 2025.
3
Effectiveness of COVID-19 vaccines against severe COVID-19 among patients with cancer in Catalonia, Spain.西班牙加泰罗尼亚地区癌症患者感染 COVID-19 疫苗对重症 COVID-19 的有效性。
Nat Commun. 2024 Jun 19;15(1):5088. doi: 10.1038/s41467-024-49285-y.
4
Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE.免疫功能低下患者中mRNA-1273和BNT162b2的免疫原性：采用GRADE的系统评价和荟萃分析
Infect Dis Ther. 2024 Jul;13(7):1419-1438. doi: 10.1007/s40121-024-00987-2. Epub 2024 May 27.
5
mRNA vaccines against SARS-CoV-2 induce divergent antigen-specific T-cell responses in patients with lung cancer.mRNA 疫苗针对 SARS-CoV-2 可诱导肺癌患者产生不同的抗原特异性 T 细胞反应。
J Immunother Cancer. 2024 Jan 4;12(1):e007922. doi: 10.1136/jitc-2023-007922.
6
mRNA-based Vaccines Targeting the T-cell Epitope-rich Domain of Epstein Barr Virus Latent Proteins Elicit Robust Anti-Tumor Immunity in Mice.基于 mRNA 的疫苗针对 Epstein Barr 病毒潜伏蛋白的 T 细胞表位丰富域，在小鼠中引发了强大的抗肿瘤免疫。
Adv Sci (Weinh). 2023 Dec;10(35):e2302116. doi: 10.1002/advs.202302116. Epub 2023 Oct 27.
7
Immunodiagnosis - the promise of personalized immunotherapy.免疫诊断——个性化免疫治疗的前景。
Front Immunol. 2023 Jul 13;14:1216901. doi: 10.3389/fimmu.2023.1216901. eCollection 2023.
8
Bibliometric analysis of RNA vaccines for cancer.癌症 RNA 疫苗的文献计量分析。
Hum Vaccin Immunother. 2023 Aug 1;19(2):2231333. doi: 10.1080/21645515.2023.2231333. Epub 2023 Jul 18.
9
Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors.免疫检查点抑制剂治疗的癌症患者接种第三剂 SARS-CoV-2 mRNA-BNT162b2 疫苗后的免疫相关不良事件和疾病结局。
Cancer Immunol Immunother. 2023 Oct;72(10):3217-3228. doi: 10.1007/s00262-023-03489-1. Epub 2023 Jul 10.
10
A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers.三剂 mRNA 新冠疫苗接种方案在实体癌患者中产生了合适的免疫原性和令人满意的疗效。
Vaccines (Basel). 2023 May 23;11(6):1017. doi: 10.3390/vaccines11061017.
本文引用的文献
1
Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.奥密克戎新冠病毒变体：新冠疫情的新篇章。
Lancet. 2021 Dec 11;398(10317):2126-2128. doi: 10.1016/S0140-6736(21)02758-6. Epub 2021 Dec 3.
2
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer.在癌症患者中，加强针在增强对 COVID-19 疫苗的免疫应答方面的效果。
Cancer Cell. 2022 Jan 10;40(1):3-5. doi: 10.1016/j.ccell.2021.11.006. Epub 2021 Nov 16.
3
Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients.癌症患者对新冠病毒mRNA疫苗的中和抗体反应受损。
Cell Biosci. 2021 Nov 21;11(1):197. doi: 10.1186/s13578-021-00713-2.
4
Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies.B细胞源性血液系统恶性肿瘤患者对SARS-CoV-2加强疫苗接种的抗刺突抗体反应
Cancer Cell. 2021 Oct 11;39(10):1297-1299. doi: 10.1016/j.ccell.2021.09.001. Epub 2021 Sep 7.
5
Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce.在高度接种疫苗的医疗系统工作人员中出现的新冠病毒感染复发现象。
N Engl J Med. 2021 Sep 30;385(14):1330-1332. doi: 10.1056/NEJMc2112981. Epub 2021 Sep 1.
6
Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2.与年龄相关的对 SARS-CoV-2 疫苗 BNT162b2 的免疫反应异质性。
Nature. 2021 Aug;596(7872):417-422. doi: 10.1038/s41586-021-03739-1. Epub 2021 Jun 30.
7
Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors.COVID-19 患者、医护人员和恢复期血浆捐献者中针对 SARS-CoV-2 刺突的中和抗体。
JCI Insight. 2020 Nov 19;5(22):143213. doi: 10.1172/jci.insight.143213.
Zotero 插件